Major retirement legislation that would impact tens of millions of Americans hangs in the balance as Congress takes its summer break.

Despite individual cases of generic drug price increases, the overall trend of costs has continued to move downward.

By the end of 2017, the average premium of an individual plan was nearly identical to that of a small group or large group plan.

Once burdened with a compliance albatross, retirement plan sponsors are beginning to see the light.